REG - Genedrive PLC - Equity Prepayment Facility drawdown

GenedriveAnnouncement

02/06/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230602:nRSB5269Ba&default-theme=true

RNS Number : 5269B  Genedrive PLC  02 June 2023

genedrive plc

("genedrive" or the "Company")

 

Equity Prepayment Facility drawdown

 

genedrive plc (LSE: GDR), the point of care molecular diagnostics company,
today announces a first £300,000 draw down under the terms of the £5m Equity
Prepayment Facility, which was previously announced by the Company on 31 March
2023. Investors have been granted 682,730 warrants equal to 40% of this
drawdown divided by the Reference Price of 17.57648 pence. The exercise price
of the warrants payable to the Company will be 140% of the Reference Price
equating to 24.6071 pence.

 

Capitalised terms in this announcement shall, unless the context demands
otherwise, bear the meanings given to such terms in the announcement of the
Facility made via RNS on 31 March 2023.

 

 

For further information, please contact:

 

 genedrive plc                       +44 (0) 161 989 0245
 David Budd (CEO) / Russ Shaw (CFO)

 Peel Hunt LLP - Nominated Adviser, Joint Broker                                                    +44 (0) 20 7148 8900
 James Steel / Oliver Duckworth

 finnCap Ltd - Joint Broker                        +44 (0) 20 7220 0500
 Geoff Nash / George Dollemore

 Walbrook PR - Financial PR & IR Adviser                     +44 (0) 20 7933 8780
 Paul McManus / Anna Dunphy          Or Genedrive@walbrookpr.com (mailto:Genedrive@walbrookpr.com)

 

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com) )

 

genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need molecular diagnostics platform for the diagnosis of infectious
diseases and for use in patient stratification (genotyping), pathogen
detection and other indications. The company are currently developing a
genetic test for CYP2C19 metaboliser status.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUPPQUPWGGP